California SJS Product Liability: What to Know About Suing Drug Manufacturers
TL;DR: If you or a loved one developed Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN) after taking a medication, California law may allow claims against certain entities in the distribution chain. Strong cases typically include clear medical documentation, a precise medication timeline, and expert causation analysis. Claims and defenses vary, with limits on strict design-defect liability for prescription drugs, learned intermediary principles, and potential federal preemption (especially for generics). Speak with counsel promptly to preserve evidence and meet deadlines.
What Is SJS/TEN and Why It Matters for Product Liability
Stevens-Johnson Syndrome (SJS) and its more severe form, Toxic Epidermal Necrolysis (TEN), are rare but serious reactions often triggered by medications. They can cause widespread skin detachment, mucosal injury, hospitalization, and long-term complications. In product liability, the link between a drug and an adverse reaction, plus what the manufacturer knew or should have known, can be central to liability.
Who You Can Potentially Sue
Depending on the facts, potential defendants in California may include:
- Brand-name manufacturers (including, in some circumstances, where the patient ingested a generic equivalent). See T.H. v. Novartis.
- Generic manufacturers, recognizing that many claims are limited by federal preemption. See PLIVA v. Mensing and Mutual Pharmaceutical v. Bartlett.
- Distributors and repackagers, as part of the distribution chain. See Vandermark v. Ford.
- Pharmacies in limited circumstances (e.g., misfills, compounding errors, or independent negligence). Pharmacists generally have no duty to warn patients of a prescription drug’s risks because the duty to warn typically runs to the prescriber under the learned intermediary doctrine. See Murphy v. E.R. Squibb.
Legal Theories Commonly Used in California Drug Cases
- Failure to warn: Claims that labeling, packaging, Medication Guides, or communications did not adequately warn of known or reasonably knowable risks. California applies the learned intermediary doctrine for prescription drugs. See Carlin v. Superior Court.
- Manufacturing defect: Allegations that a particular lot or unit deviated from specifications, making it unreasonably dangerous.
- Negligence: Claims that the manufacturer or others failed to use reasonable care in testing, monitoring adverse events, updating warnings, or otherwise safeguarding users.
- Breach of warranty: Express or implied warranties that were not met.
- Design defect (limited for Rx drugs): Strict-liability design defect claims against prescription drug manufacturers are generally barred in California under comment k. See Brown v. Superior Court. Different analyses may apply to non-prescription products.
Federal preemption can affect certain claims. For brand-name drugs, failure-to-warn claims are often not preempted absent clear evidence the FDA would have rejected the warning. See Wyeth v. Levine and Merck v. Albrecht. For generic drugs, many failure-to-warn and design-defect claims are preempted. See Mensing and Bartlett.
Proving Causation in SJS/TEN Cases
Establishing causation typically requires:
- Medical documentation of SJS/TEN diagnosis, hospitalization records, dermatology and ophthalmology consults, and biopsy if performed.
- A clear medication timeline: prescription records, pharmacy fills, lot information if available, and when symptoms first appeared.
- Differential diagnosis: expert opinions ruling out alternative causes (e.g., infections) and addressing re-challenge data if any.
- Scientific support: published literature, adverse event reports, labeling changes, or regulatory communications related to the drug and SJS/TEN.
Early preservation of medication containers, pharmacy leaflets, and photographs of injuries can strengthen your case.
Evidence to Gather Right Away
- All medication lists, including over-the-counter and herbal products
- Pharmacy printouts and prescription histories
- Hospital and specialist records, lab results, and imaging
- Employment and school records documenting time lost
- Insurance communications and Explanation of Benefits (EOBs)
- Photos of injuries and healing progression
- Communications with prescribers and pharmacists
Your attorney can send preservation letters to manufacturers and others to safeguard testing, batch, and pharmacovigilance records.
Practical Tips
- Photograph rashes and eye involvement daily during the acute phase and recovery.
- Keep original pill bottles, boxes, and pharmacy leaflets to capture NDC, lot, and fill dates.
- Request complete hospital records, including dermatology and ophthalmology notes, before discharge if possible.
- Avoid posting case specifics on social media; screenshots can be discoverable.
- Speak with counsel early to evaluate preemption, learned intermediary, and timing issues.
Quick Checklist
- Medication timeline (start/stop dates for each drug)
- Pharmacy records and receipts
- Hospital admission/discharge summaries
- Specialist consults and biopsy/pathology, if any
- Photos of injuries and healing
- Work/school absence documentation
- Insurance EOBs and bills
- List of all treating providers and contact info
Potential Damages
Recoverable damages in a successful California product liability action may include medical expenses, future care and rehabilitation, lost income and earning capacity, pain and suffering, and disfigurement. In appropriate cases, punitive damages may be available if the plaintiff proves malice, oppression, or fraud under Cal. Civ. Code § 3294. Family members may also have derivative claims, and wrongful death and survival remedies may be available if a loved one passed away due to SJS/TEN.
Timing Considerations
California generally provides a two-year limitations period for personal injury and wrongful death (Cal. Code Civ. Proc. § 335.1), subject to the discovery rule (Fox v. Ethicon). Wrongful death and survival actions have specific statutory frameworks (§ 377.60; § 377.30). Because accrual and tolling are fact-dependent, consult counsel promptly.
How Federal Regulation Interacts With California Law
Drug cases often turn on the FDA regulatory record, including labeling changes, Medication Guides, safety communications, and post-marketing data. For brand-name drugs, failure-to-warn claims are often viable under Wyeth v. Levine, unless there is clear evidence the FDA would have rejected the warning, a question courts assess under Merck v. Albrecht. For generic drugs, many failure-to-warn and design-defect claims are preempted under Mensing and Bartlett. Plaintiffs often focus on non-preempted theories and fact patterns.
FAQ
Do I have a case if I took a generic drug?
Possibly. Many claims against generics face federal preemption, but avenues may exist depending on facts and defendants. A detailed review is essential.
Who must be warned under the learned intermediary doctrine?
Typically the prescribing physician, not the patient directly, for prescription drugs in California.
How soon should I contact a lawyer?
Immediately. Early action helps preserve evidence and avoid missing deadlines.
What if the hospital did not biopsy?
You can still pursue a claim with clinical diagnosis, specialist notes, and other medical evidence.
Will I need expert witnesses?
Yes. Causation and warnings issues generally require qualified medical and regulatory experts.
What to Expect When You Contact Our Firm
- Free case evaluation
- Rapid review of your medication history and medical records
- Assessment of potential defendants and claims
- Coordination with medical experts experienced in SJS/TEN
- Transparent discussion of fees and case timelines
We act quickly to preserve evidence and evaluate whether litigation, negotiation, or other resolution is in your best interest.
Take the Next Step
If you suffered SJS/TEN after taking a prescription or over-the-counter medication, contact us for a confidential consultation. The sooner you speak with counsel, the better we can evaluate claims, secure evidence, and navigate applicable deadlines. Contact us.
Key Authorities (Select)
- Vandermark v. Ford Motor Co., 61 Cal.2d 256 (1964)
- Brown v. Superior Court, 44 Cal.3d 1049 (1988)
- Carlin v. Superior Court, 13 Cal.4th 1104 (1996)
- T.H. v. Novartis Pharmaceuticals Corp., 4 Cal.5th 145 (2017)
- Wyeth v. Levine, 555 U.S. 555 (2009)
- PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011)
- Mutual Pharmaceutical Co. v. Bartlett, 570 U.S. 472 (2013)
- Merck Sharp & Dohme Corp. v. Albrecht, 139 S. Ct. 1668 (2019)
Disclaimer: This post provides general information about California law and is not legal advice. It does not create an attorney-client relationship. Laws and deadlines are subject to change and vary by facts. Consult a qualified California attorney about your specific circumstances.